Skip to main content

Drug Interactions between Onfi and rifabutin

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

rifabutin cloBAZam

Applies to: rifabutin and Onfi (clobazam)

Rifampin may decrease benzodiazepine serum levels. The mechanism is probably related to stimulation of the hepatic metabolism of benzodiazepines. Diazepam and triazolam have been specifically studied in this regard, although other benzodiazepines also may interact with rifampin. Additionally, rifabutin may have an interaction with benzodiazepines similar to that of rifampin.

References

  1. Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ (1981) "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther, 29, p. 671-8
  2. Villikka K, Kivisto KT, Backman JT, Olkkola KT, Neuvonen PJ (1997) "Triazolam is ineffective in patients taking rifampin." Clin Pharmacol Ther, 61, p. 8-14
  3. Strayhorn VA, Baciewicz AM, Self TH (1997) "Update on rifampin drug interactions, III." Arch Intern Med, 157, p. 2453-8

Switch to consumer interaction data

Drug and food interactions

Moderate

cloBAZam food

Applies to: Onfi (clobazam)

GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents. Use in combination may result in additive central nervous system depression and/or impairment of judgment, thinking, and psychomotor skills.

MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol. Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.

References

  1. Warrington SJ, Ankier SI, Turner P (1986) "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology, 15, p. 31-7
  2. Gilman AG, eds., Nies AS, Rall TW, Taylor P (1990) "Goodman and Gilman's the Pharmacological Basis of Therapeutics." New York, NY: Pergamon Press Inc.
  3. (2012) "Product Information. Fycompa (perampanel)." Eisai Inc
  4. (2015) "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc
View all 4 references

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer